CHF Solutions Promotes Nestor Jaramillo, Jr. to President and Chief Operating Officer
June 25 2020 - 8:30AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
improving the lives of patients suffering from fluid overload,
today announced the promotion of Nestor Jaramillo, Jr. to President
and Chief Operating Officer, effective July 1, 2020. In his
expanded role, Mr. Jaramillo now will have responsibility for
Operations, Engineering, Product Development, Regulatory, Quality,
Clinical Affairs, Reimbursement and Human Resources, in addition to
the Commercial functions.
Since joining CHF Solutions in May 2019, Mr. Jaramillo has led
the company’s commercialization growth, refocusing the company’s
strategy to continue growth in the chronic care of heart failure
patients, to expand opportunities in the acute needs in critical
care, and to develop the life-saving opportunities in pediatric
care. He has recruited and organized the company’s exceptionally
talented marketing, sales, and clinical education teams, who are
instrumental in continuing to grow the value of CHF Solutions.
Prior to joining CHF Solutions, Mr. Jaramillo was President and
Chief Executive Officer of Innerspace Neuro Solutions, Inc., a
commercial-stage medical technology company that developed,
manufactured, and distributed an intracranial pressure monitoring
system. He also worked in a variety of capacities at startup
Transoma Medical, as well as Medtronic and St. Jude Medical (now
Abbott). In addition to his medical device experience, Mr.
Jaramillo also spent seven years as a managing director in
healthcare investment banking at both Cherry Tree & Associates
and Craig-Hallum Capital in Minneapolis. He holds an electrical
engineering degree from the University of North Dakota and a Master
of Business Administration from the University of St. Thomas in
Minnesota.
“Nestor has had a strong impact on our commercial success over
the last 14 months,” said John Erb, CEO of CHF Solutions. “Under
Nestor’s leadership, we have expanded our strategy into critical
care and pediatrics, including the recent launch of the Aquadex
SmartFlow™ system for use in adult and pediatric patients weighing
over 20 kg. I look forward to continuing to work with Nestor as the
company improves the lives of patients suffering from fluid
overload.”
"It's an honor to continue to help CHF Solutions deliver this
innovative ultrafiltration therapy to many more patients," said
Jaramillo. “We have an outstanding organization, with talented
people dedicated to changing the lives of patients."
About CHF SolutionsCHF Solutions, Inc. (CHFS)
is a medical device company dedicated to changing the lives of
patients suffering from fluid overload through science,
collaboration, and innovation. The company is focused on
developing, manufacturing and commercializing the Aquadex
SmartFlow™ system for ultrafiltration therapy. CHF Solutions is
headquartered in Minneapolis, Minn., with wholly-owned subsidiaries
in Australia and Ireland. The company has been listed on the Nasdaq
Capital Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements about the future
growth of the company’s business and the company’s ability to
improve patients’ lives. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, the risks associated with our expectations regarding
the potential impacts of the COVID-19 pandemic on our business
operations, the risks associated with our ability to execute on our
commercial strategy, the possibility that we may be unable to raise
sufficient funds necessary for our anticipated operations, our
post-market clinical data collection activities, benefits of our
products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
our ability to integrate acquired businesses, our expectations
regarding anticipated synergies with and benefits from acquired
businesses, and other risks and uncertainties described in our
filings with the SEC. Forward-looking statements speak only as of
the date when made. CHF Solutions does not assume any obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024